Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T regulatory cell therapy in COVID-19 induced ARDS
NCT04737161Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord blood regulatory T cells in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Stanford University. Primary endpoints: Number of participants that experience the occurrence of infusion associated adverse events, Number of patients that experience treatment emergent adverse events and 1 more. Planned start Mar 2021; status: withdrawn.
02
Drugs
umbilical cord blood regulatory T cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04737161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737161.